Pharma BD Deal Intelligence
A clean pivot deal: DSM paid $2.24B for Roche's Vitamins division, cleared FTC's phytase divestiture to BASF, and completed on schedule as DSM Nutritional Products in September 2003 — though Roche kept every price-fixing liability from the unit it sold.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche chairman Franz Humer framed the EUR 2.25B sale as a focus move on Roche's 'two high-tech pillars, pharmaceuticals and diagnostics'; Roche kept all…
EU Commission opened in-depth Phase II probe into the DSM/Roche Vitamins deal citing horizontal overlap concerns, particularly in feed enzymes.
FTC alleged the deal would violate Section 7 of the Clayton Act in feed phytase markets; DSM agreed to divest the phytase business to BASF as the consent…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
DSM acquired Roche's Vitamins & Fine Chemicals division for EUR 2.25B (approximately $2.24B) as part of Roche's refocus on its pharmaceuticals and diagnostics pillars following its vitamin price-fixing settlements. The transaction cleared on conditions, with the FTC requiring divestiture of the feed-phytase business to BASF and the EU Commission granting clearance in July 2003. DSM completed the acquisition with effect from September 30, 2003 and renamed the business DSM Nutritional Products.
$2.4B Roche Vitamins & Fine Chemicals annual sales pre-deal (~EUR 2.4B / ~USD equivalent)
Vitamins, carotenoids and fine chemicals are bulk B2B ingredients sold to food, animal feed, pharmaceutical and cosmetics manufacturers. The category sits upstream of finished pharmaceutical and nutritional products and was historically dominated by a small group of integrated chemical producers — Roche, BASF, Takeda, Rhone-Poulenc — several of which were sanctioned in the late-1990s vitamin price-fixing cartel.
The bulk vitamins, carotenoids and fine chemicals supply chain in 2002-2003 was a concentrated B2B oligopoly recovering from the 1999-2001 vitamin price-fixing cartel cases (US DOJ and EU Commission actions against Roche, BASF, Aventis/Rhone-Poulenc, Takeda and others). Roche's Vitamins & Fine Chemicals division was the global #1 with ~33% share, ~EUR 2.4B annual sales and 7,500 employees, supplying citric acid, beta-carotene, vitamins A/B/C/E and feed enzymes. DSM acquired the unit for an originally announced EUR 2.25B (final paid EUR 1.95B after FX/economic adjustments) to anchor its Vision 2005 life-sciences pivot. Antitrust posed the gating risk: the FTC initially alleged the deal violated the Clayton Act due to overlap in feed phytase, and the European Commission cleared after detailed review on July 23, 2003; DSM divested the phytase business to BASF as a remedy. Roche retained pre-existing price-fixing liabilities. Closing on September 30, 2003 created DSM Nutritional Products, which remains a leading global supplier (now part of dsm-firmenich after the 2023 merger). Key competing suppliers post-deal: BASF Human & Animal Nutrition, Lonza, Adisseo, and Chinese entrants (NHU, CSPC, Zhejiang Medicine).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| DSM N.V. / Roche Vitamins and Fine Chemicals Division (this deal) | 2002 | $2.2B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2002 deals